Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10

Joshua E. Allen, Varun V. Prabhu, Mala Talekar, A. Pieter J. van den Heuvel, Bora Lim, David T. Dicker, Jennifer L. Fritz, Adam Beck, and Wafik El-Deiry

Abstract

ONC201/TIC10 is a small-molecule inducer of the TRAIL gene under current investigation as a novel anticancer agent. In this study, we identify critical molecular determinants of ONC201 sensitivity offering potential utility as pharmacodynamic or predictive response markers. By screening a library of kinase siRNAs in combination with a subcytotoxic dose of ONC201, we identified several kinases that ablated tumor cell sensitivity, including the MAPK pathway–inducer KSR1. Unexpectedly, KSR1 silencing did not affect MAPK signaling in the presence or absence of ONC201, but instead reduced expression of the antiapoptotic proteins FLIP, Mcl-1, Bcl-2, cIAP1, cIAP2, and survivin. In parallel to this work, we also conducted a synergy screen in which ONC201 was combined with approved small-molecule anticancer drugs. In multiple cancer cell populations, ONC201 synergized with diverse drug classes, including the multikinase inhibitor sorafenib. Notably, combining ONC201 and sorafenib led to synergistic induction of TRAIL and its receptor DR5 along with a potent induction of cell death. In a mouse xenograft model of hepatocellular carcinoma, we demonstrated that ONC201 and sorafenib cooperatively and safely triggered tumor regressions. Overall, our results established a set of determinants for ONC201 sensitivity that may predict therapeutic response, particularly in settings of sorafenib cotreatment to enhance anticancer responses.

Introduction

ONC201/TIC10 is a small molecule that was discovered due to its ability to engage the endogenous TNF-related apoptosis-inducing ligand (TRAIL) cell death pathway that triggers cell death in tumor cells with a favorably wide therapeutic window. We previously reported the discovery and selective advantages of this small molecule compared with other TRAIL-based agents, along with preclinical efficacy, safety, and mechanism of action studies. These studies revealed substantial monoa
genic sensitivity in several tumors types that appeared to be driven by a late-stage dual inactivation of Akt and MAPK signaling to boost downstream production of TRAIL through activation of Foxo3a. ONC201 is currently in clinical trials in advanced cancer patients to evaluate monoagent safety and preliminary antitumor activity in selected solid and liquid tumors.

We previously reported genetic determinants of sensitivity to TRAIL (2) and therapeutic strategies to increase cancer cell sensitivity to TRAIL, such as combination therapy with sorafenib (3). Our previous studies found that ONC201-mediated apoptosis is Rax dependent in HCT116 cells, as is the case with recombinant TRAIL (1, 2). In this study, unbiased genetic and small-molecule approaches to identify determinants of ONC201 sensitivity were pursued in parallel and to augment the antitumor activity of ONC201 through combination therapy. In addition to basic findings that include a novel relationship that we identify between KSR1 and regulators of apoptosis, these studies also identify several predictive markers of ONC201 response and drug combinations that warrant investigation in future monoagent and combinatorial clinical studies.

Materials and Methods

Cell culture and reagents

Cell lines were obtained from the ATCC and were cultured under recommended conditions in log-phase growth. Sorafenib was kindly provided by Charles D. Smith, Medical University of South Carolina, Charleston, South Carolina. Sorafenib was formulated in DMSO (Sigma-Aldrich) for in vitro studies and in 50% ethanol (Sigma-Aldrich) and 50% Cremophor EL (Sigma-Aldrich) for in vivo studies. ONC201 was synthesized as a salt by Provid Pharmaceuticals, and structural integrity was validated by nuclear magnetic resonance and X-ray crystallography. ONC201 was formulated in DMSO for in vitro studies and
phosphate-buffered saline for in vivo studies. The FDA Approved Oncology Set IV was obtained from the NCI.

siRNA kinase library screen

HCT116 p53−/− cells were transfected at 20,000 cells per well in 96-well plates. Cells were transfected with the Stealth RNAi human kinase library (Life Technologies) using RNAiMax (Life Technologies) in Optimem (Life Technologies). Scramble and AllStars Hs Cell Death Control siRNA (Qiagen) were used as negative and positive controls, respectively. Transfection was carried out overnight, and the following day complete media containing ONC201 or DMSO were added to the plates following removal of the transfection media. CellTiterGlo (Promega) analysis was performed according to the manufacturer's instructions at indicated time points.

Small-molecule synergy screen

Procedures were performed with a Biomek 2000 robot using pin tools for drug treatment. Cells were seeded at 5 × 10^4 cells/mL in 96-well black-wall plates, and treatment was performed 12 hours later. Combinatorial activity was initially assessed by calculating the difference between the observed activity with the combination and the sum of the monoagent activities.

Cell-based assays

Cell viability, Western blot analysis, and cell-cycle flow-cytometry analysis were performed as previously described (1). Cell surface TRAIL and DR5 were assessed following fixation with 4% paraformaldehyde in PBS for 20 minutes, rinsed in PBS, incubated overnight at 1:200 with anti-TRAIL (Abcam) or anti-DR5 antibodies, rinsed in PBS, incubated with fluorophore-conjugated secondary antibodies (Thermo Scientific Pierce) at 1:250 for 30 minutes, and analyzed by flow cytometry. pERK was assessed with an antibody for p-T202/Y204 (Cell Signaling Technology), and pAkt was assessed with antibody for pT308 (Cell Signaling Technology).

In vivo studies

Six-week-old athymic nude mice were obtained from Charles River Laboratories. HepG2 cells (10^7) in 200 μL (1:1, PBS: Matrigel) were injected into each rear flank. Measurable tumors were assessed 1 week later. Treatment was then initiated as indicated. Sorafenib and ONC201 were administered as 100 μL solutions by oral gavage. ONC201 was administered 12 hours following sorafenib treatment. Tumor volume was assessed with digital calipers and calculated as a spheroid. Tumor dimensions and body weights were assessed twice a week. IHC (Vector Labs) and terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL; Millipore) analyses were performed as previously described (1).

Statistical analysis

Pairwise comparisons were assessed by a two-tailed Student t test. Combination indices were calculated using the Chou–Talalay method and CalcuSyn software.

Results

Identification of kinase regulators of ONC201 sensitivity

We conducted a siRNA screen to identify kinases that affect ONC201 response in cancer cells to potentially gain mechanistic insight regarding ONC201 and identify molecular targets for combination therapy to improve the activity of ONC201 and/or predict response. A siRNA library targeting 636 kinases was used for the screen along with 1 μM dose of ONC201 in HCT116 p53−/− cells. The screen identified a number of candidate positive and negative regulators of ONC201 sensitivity at 12 and 36 hours after treatment (Fig. 1A). As expected, there was a general trend toward decreased cell viability with knockdown of most kinases themselves, though the decreased cell viability was typically modest in magnitude (<30%). The top three to four positive and negative modulators of ONC201 sensitivity at each evaluated time point were selected for validation studies (Supplementary Table S1), which identified four kinases that enhance response to ONC201 following knockdown at 36 hours after treatment in HCT116 p53−/− cells: DGKD, SGKL, STK123, and KSR1 (Supplementary Table S2 and Supplementary Fig. S1). Enhanced ONC201 efficacy with knockdown of these four kinases is also apparent at 48 but not 24 hours after treatment (Fig. 1B), suggesting that the molecular mechanism of sensitivity may involve the late apoptotic effects rather than the early signaling effects.

Network analysis of these four kinases that regulate ONC201 sensitivity and the previously described mechanism of ONC201 revealed rational overlap of signaling pathways with some kinases. Among the four identified kinases, KSR1 possessed the most direct connections to the putative mechanism of ONC201 that involves the dual inhibition of Akt and the MAPK pathway (Fig. 1C). KSR1 is described as a MAPK scaffold protein that positively regulates the MAPK signaling pathway (4). Western blot analysis confirmed knockdown of KSR1 at the protein level by siRNA and that ONC201 has a modest negative effect on KSR1 expression as a monoagent (Fig. 1D). Cell death assays with ONC201 and siRNA targeting KSR1 revealed that KSR1 knockdown significantly enhanced cell death induced by ONC201 (Fig. 1E). Also in support of a MAPK-independent effect, knockdown of KSR1 did not enhance the effects of the dual EGFR/HER2 small-molecule inhibitor (Supplementary Fig. S2).

We next investigated whether KSR1 knockdown affected the amount or kinetics of TRAIL or DR5 production that is stimulated downstream by ONC201. No effect was observed on these parameters with knockdown of KSR1 (Supplementary Fig. S3). Consistent with this notion, the concentration threshold and magnitude of MAPK and Akt signaling inhibition was not affected by KSR1 knockdown (Supplementary Fig. S4). These observations suggested that the ability of KSR1 to sensitize cancer cells to ONC201 involves factors that lie downstream of TRAIL production.

Identification of small molecule anticancer drugs that synergize with ONC201

In parallel to the siRNA screen, we screened for FDA-approved drugs that synergize with ONC201 in a panel of human cancer cell lines that represent a diverse array of solid tumors (brain, breast, colon, liver, lung, and ovarian) to potentially improve the antitumor activity of ONC201. For this screen, we utilized the NCI DTP Approved Set IV that includes 101 small molecules approved by the FDA for an indication in oncology. To enable sufficient evaluation of synergism, we chose to screen using a subcytotoxic dose of ONC201 (1 μmol/L) and tested multiple doses of the approved oncology drugs (10 nmol/L, 100 nmol/L, and 1 μmol/L), given their wide range of GI50 values among each other and across cell lines. Using cell viability assays following 72 hours of treatment, we identified 33 approved oncology drugs...
that combined with ONC201 to give a >20% reduction in cell viability over the expected reduction in cell viability, which was calculated as the sum of the observed monoagent activity (Fig. 2A). Twelve of these agents synergized under more than a single condition tested in the screen (Supplementary Fig. S5A).

Analyzing the classes of drugs tested in the screen revealed that ONC201 synergizes with a wide array of drug classes, though synergy was not ubiquitous within any particular class (Supplementary Fig. S5B). Notable exceptions were the absence of synergy observed with any specific mTOR or EGFR/MAPK signaling inhibitors. This observation is in accordance with previous studies of ONC201 that demonstrated the ablation of Akt and MAPK signaling following ONC201 monoagent treatment in HCT116 cells (1). Lack of synergy with specific antiangiogenic agents were also noted, which is expected as angiogenesis is not represented in standard cell culture models. Alkylating agents and nucleotide synthesis inhibitors possessed the largest number of agents that synergized with ONC201, though this can be attributed to the increased prevalence of these agents among the approved small-molecule oncology drugs (Supplementary Fig. S5C).

We selected eight approved oncology drugs for validation based on the amount of synergy and the number of instances of synergy observed in the screen: azacitidine, bortezomib, dacarbazine, hydroxyurea, pralatrexate, sorafenib, topotecan, and vismodegib. We evaluated the combinatorial activity of these agents with ONC201 in multidose cell viability assays in the cell lines

Figure 1.
siRNA screen identifies kinase regulators of ONC201 sensitivity. A, decrease in cell viability in HCT116 cells associated with the siRNA alone (y-axis) or the difference in observed and predicted activity in cell viability associated with the combination of ONC201 treatment (1 μmol/L) and knockdown by siRNA (x-axis). B, cell viability in HCT116 cells following ONC201 treatment (1 μmol/L) and/or siRNA knockdown at 24 or 48 hours after treatment (n = 3). Quantification (top) and raw data (bottom) are shown. *, P < 0.05, compared with 48 hours after ONC201 treatment and control siRNA by the two-tailed Student t test. C, network analysis of ONC201 kinase regulators (blue) and putative mechanism of action (green). D, Western blot analysis of HCT116 cells treated with DMSO or ONC201 (5 μmol/L) with or without siRNA-mediated knockdown of KSR1 (60 hours). E, sub-G1 DNA content analysis following treatment with ONC201 (5 μmol/L) or sorafenib at indicated concentrations (72 hours; n = 3). *, P < 0.05, by the two-tailed Student t test. FLIP and Mcl-1 as Regulators of ONC201 Sensitivity
where synergy was previously demonstrated (Supplementary Fig. S6A). The combination of ONC201 with these agents generally resulted in a complete elimination of tumor cells at the higher tested doses.

We prioritized the validation of combinations as a function of synergistic activity as well as overall efficacy (Fig. 2B). Six of the nine validated agents met the prioritization criteria of imparting >20% increase in cell viability over the expected observations and a >25% reduction in absolute cell viability with the combination: azacitidine, bortezomib, dacarbazine, hydroxyurea, sorafenib, and vismodegib (Fig. 2C). Synergy between TRAIL and bortezomib, dacarbazine, hydroxyurea, or sorafenib has been previously reported (3, 5, 6). Examining monoagent and combinatorial activity, we found that adding vismodegib to ONC201 did not result in improved activity compared with monoagent ONC201, but rather reversed surprising agonistic growth effects of monoagent vismodegib that we observed in several cell lines. Sorafenib possessed the highest number of data points in the validation dataset that met our prioritization criteria, demonstrating synergy in HCT116 and A172 cell lines at multiple doses (Supplementary Fig. S6B).

**ONC201 synergizes with sorafenib in vitro and in vivo**

We next explored the activity of ONC201 alone and in combination with sorafenib in its approved indications, hepatocellular carcinoma and renal cell carcinoma. The combination of sorafenib and ONC201 resulted in synergistic reduction of cell viability in HepG2 cells, but not other cell lines in the panel (Fig. 3A; Supplementary Fig. S7 and Supplementary Table S3). Synergy was objectively confirmed by combination indices using the Chou–Talalay method (Supplementary Table S4).

We next investigated the possibility that ONC201 and sorafenib synergistically induce apoptosis in HepG2 cells. We found that ONC201 in combination with sorafenib cooperatively induced cell death that was significantly greater than either of the monoagents (Fig. 3B). Further supporting evidence of
apoptosis was obtained by Western blot analysis of caspase-8 activation and cleavage of PARP and DNA fragmentation (Fig. 3C and Supplementary Fig. S8). Together, this evidence indicates that ONC201 and sorafenib synergistically induce apoptosis in HepG2 human hepatocellular carcinoma cells.

We then evaluated the antitumor activity of ONC201 and sorafenib alone and in combination in HepG2 subcutaneous xenografts in athymic nude mice. Sorafenib was administered once a day for days 1 to 5 and days 8 to 12 at 40 mg/kg orally, and ONC201 was administered once a week at 25 mg/kg. ONC201 and sorafenib monoagent therapies induced partial regressions of these xenograft tumors, which do not grow aggressively in vivo, as previously reported (Fig. 3D and Supplementary Fig. S9A). In contrast with in vitro results, ONC201 exhibited a more potent antitumor effect than sorafenib under these conditions. The combination produced a significantly increased rate of complete tumor regressions (8 of 10 tumors) compared with ONC201 (4 of 10) or sorafenib (0 of 10) alone following 2 weeks of this treatment (Fig. 3E). The combination was well tolerated with no overt signs of toxicity or loss of body weight (Supplementary Fig. S9B).

Sorafenib and KSR-1 affect ONC201 response by regulating FLIP, IAP, and Bcl-2 proteins

We investigated the effects of ONC201 and sorafenib, alone and in combination, on surface TRAIL and DR5 that together act as apoptosis initiators. ONC201 consistently upregulated surface TRAIL and DR5, as previously reported (1), and sorafenib surprisingly upregulated TRAIL in two of the three cancer cell lines. Both surface TRAIL and DR5 were cooperatively upregulated by the combination of sorafenib and ONC201 in HepG2 cells, an observation that was not evident in the other tested hepatocellular carcinoma cells that did not exhibit synergy (Fig. 4A). Cooperative induction of TRAIL and DR5 was also observed in tumor specimens from the HepG2 in vivo experiment with sorafenib and
ONC201 (Supplementary Fig. S10). Investigating effects of combinatorial sorafenib and ONC201 therapy on Akt and ERK kinase activity in a cellular context with respect to their mutual substrate Foxo3a revealed a cooperative inhibitory effect on the Akt phosphorylation site of Foxo3a (Fig. 4B). The ERK phosphorylation site of Foxo3a was eliminated by sorafenib monoagent therapy, likely due to the direct inhibition of Raf by sorafenib.

We also investigated the effects of sorafenib on apoptosis regulators that we previously described as modulators of TRAIL sensitivity (3). Among IAP and Bcl-2 family members, sorafenib downregulates expression of survivin and XIAP in HepG2 cells (Fig. 4C). Sorafenib also negatively regulated Mcl-1, Bax, Bak, cIAP1, and survivin to a moderate extent in HCT116 cells that undergo apoptosis in response to ONC201 treatment (1). By comparison, KSR1 knockdown resulted in downregulation of the antiapoptotic proteins FLIP, Mcl-2, Bcl-2, cIAP1, cIAP2, and survivin in HCT116 cells that was even more dramatic in most cases than that observed with sorafenib (Fig. 4D).

Based on these regulatory relationships and previously established relationships with TRAIL sensitivity, we investigated the effects of knocking down the caspase-8 inhibitor FLIP or the Bcl-2 family protein Mcl-1 on ONC201 sensitivity in HCT116 cells (7). We found that knockdown of either of these proteins enhanced the response to ONC201 (Fig. 4E). In addition, we found that these genetic manipulations also sensitized HepG2 cells to ONC201 (Supplementary Fig. S11). Together, these results suggest that FLIP, IAP, and Bcl-2 proteins may modulate sensitivity to ONC201 and that sensitivity to ONC201 can be increased through regulation of these proteins by sorafenib (Supplementary Fig. S12).

**Discussion**

The siRNA screen in the present studies identified several kinases that negatively regulate ONC201 response and may be evaluated as predictive markers in nascent clinical studies. It is worth noting that these markers are predictive of enhanced or blunted responses to ONC201, rather than complete presence versus complete absence of responses. In addition to serving as biomarkers, these kinases may be pharmacologically engaged directly or indirectly with other...
therapies to potentially augment ONC201 efficacy. To this effect, a number of FDA-approved anticancer therapies were identified in this study that combine with ONC201 to synergistically exert antitumor effects. The combination of sorafenib and ONC201 appears to be promising, given the prevalence of cures, and it was well tolerated in mouse models. One limitation of this study is that hepatocellular carcinoma xenografts, including HepG2 xenografts, are not as aggressive in mouse models, although the responses were impressive.

Synergy between sorafenib and TRAIL has been extensively reported in a variety of tumor types, including hepatocellular carcinoma, with sorafenib-mediated downregulation of McI-1 and FLIP being the most commonly proposed mechanism of TRAIL sensitization (3, 8–11). The mechanism of sorafenib-mediated regulation of these proteins is less clear, as reports have proposed a number of mechanisms, including inhibition of transcription through Stat3 or NF-kB, and alternative mechanisms such as inhibition of translation. These findings suggest that other mechanisms may be involved in the sensitization with ONC201, such as quinacrine, are worth investigating for combinatorial activity with ONC201 (12). By a similar notion, these findings also suggest that sorafenib may sensitize other TRAIL-based agents such as TRAIL-receptor agonists that have been developed, including antibody- and protein scaffold–based approaches (13–15).

One limitation of these studies is the somewhat ambiguous biology of KRAS, which was previously reported as a regulator of Ras signaling. Despite selecting this lead based on this canonical molecular biology, we did not observe effects on MAPK or Akt signaling, but instead discovered a novel relationship between KRAS1 and regulators of apoptosis. In support of our observations, a previous study has reported that KRAS1 sensitizes endometrial carcinoma cells to TRAIL through downregulation of FLIP that did not involve transcription or protein degradation (16). Further study will be needed to elucidate this mechanism of regulation that could involve many established regulators of FLIP, IAP, and Bcl-2 stability and expression, such as JNK (17) or NF-kB (3). Nevertheless, the involvement of these apoptotic regulators in ONC201 sensitizations suggests that combining ONC201 with direct antagonists of these proteins under clinical development, such as XIAP or Bcl-2 inhibitors, may be an effective anticancer strategy.

Disclosure of Potential Conflicts of Interest
J.E. Allen has ownership interest (including patents) in and is a consultant/ advisory board member for Oncoceutics. W.S. El-Deiry is cofounder of and has ownership interest (including patents) in Oncoceutics. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: J.E. Allen, W.S. El-Deiry
Development of methodology: J.E. Allen, B. Lim, J.L. Fritz
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.E. Allen, V.V. Prabhu, M. Talekar, A.P.J. van den Heuvel, B. Lim, D.T. Dicker, J.L. Fritz, A. Beck
Analysis and interpretation of data: (e.g., statistical analysis, biostatistics, computational analysis): J.E. Allen, V.V. Prabhu, M. Talekar, W.S. El-Deiry
Writing, review, and/or revision of the manuscript: J.E. Allen, M. Talekar, A.P.J. van den Heuvel, B. Lim, D.T. Dicker, W.S. El-Deiry
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.E. Allen, M. Talekar, A.P.J. van den Heuvel, B. Lim, D.T. Dicker, W.S. El-Deiry
Study supervision: W.S. El-Deiry

Grant Support
This work was supported by Oncoceutics and a Pennsylvania Department of Health grant awarded to Oncoceutics. W.S. El-Deiry is an American Cancer Society Research Professor.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 12, 2014; revised December 28, 2014; accepted January 5, 2015; published OnlineFirst February 13, 2015.

References
Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10

Joshua E. Allen, Varun V. Prabhu, Mala Talekar, et al.

Cancer Res  Published OnlineFirst February 13, 2015.